Acurian’s clinical trial recruitment database hits 70 million

Monday, January 23, 2012 09:37 AM

Horsham, Penn.-based Acurian, a provider of global patient enrollment and retention solutions, has expanded its opted-in database to over 70 million people. These people have self-reported specific ailments and provided permission to be contacted exclusively by Acurian for clinical trial opportunities.

In 2011, Acurian contacted over 18 million people using its proprietary recruitment database, supporting clinical trial enrollment for studies in therapeutic areas including diabetes, opioid-induced constipation, depression, asthma, COPD, back pain, bipolar disorder, female sexual dysfunction and hypertension.

While other recruitment companies and CROs maintain databases typically gathered via online disease communities, the largest of these communities is under four million individuals.

“We have a significant advantage in trial enrollment services due to the sheer size of our patient database and unparalleled access to potential trial participants,” said Rick Malcolm, Acurian’s CEO. “Only a database with this size and scope can contribute hundreds or thousands of patients quickly across multi-protocol studies. Online disease communities are an important part of the new trial landscape, but alone they simply cannot provide the patient demand for increasingly large studies or those with complicated protocol designs.”

Acurian also reported significant growth in global access to patients through both online and offline media channels. Use of social media and online health networks increased over 200% from previous years, leading to hundreds of millions of clinical trial impressions and click-throughs worldwide. Penetration via television and print led to 81% of the U.S. population being exposed to at least one clinical trial opportunity sponsored by an Acurian customer.

“Our industry is struggling to find innovative ways to manage trial costs while completing enrollment on time,” continued Malcolm. “Strategic CRO alliances and new technologies sound promising on the surface, but fall short in our opinion compared to proven solutions that combine far-reaching patient access with enrollment best practices. These solutions are available today and enable our customers to complete enrollment without adding sites or time.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs